Physician profile
Kenneth Banner
NPI 1790917813
$3,861.64
in general payments reported to CMS, 2019-2025
23 companies · $875 in 2025
The $875 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $29.18 · 2021: $205 · 2022: $694 · 2023: $905 · 2024: $979 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,689 · Education: $30.40 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,689.00 |
| Education | $30.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,075.92 | 2019-2025 | |
| Abbvie INC. | $963.85 | 2019-2025 | Linzess, Skyrizi, Creon |
| Janssen Biotech, INC. | $398.68 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.29 | 2024-2025 | Xifaxan, Relistor |
| Pfizer INC. | $211.91 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.20 | 2021-2024 | Eohilia, Gattex |
| Intercept Pharmaceuticals, INC. | $129.81 | 2024-2025 | |
| Madrigal Pharmaceuticals | $125.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $118.68 | 2023-2025 | Rebyota |
| Celgene Corporation | $68.15 | 2022 | |
| Lilly USA, LLC | $60.16 | 2025 | Omvoh |
| Evoke Pharma, INC. | $40.72 | 2023 | Gimoti |
| Ardelyx, INC. | $38.73 | 2022-2023 | Ibsrela |
| Capsovision, INC. | $38.54 | 2023-2025 | Capsocam Plus |
| Regeneron Healthcare Solutions, INC. | $21.15 | 2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $21.00 | 2023 | Fibroscan |
| Biocon Biologics INC | $19.71 | 2025 | Yesintek |
| Micro-Tech Endoscopy USA, INC. | $19.05 | 2019 | |
| Qol Medical, LLC | $19.01 | 2019 | |
| Amgen INC. | $18.92 | 2025 | Uplizna |
| Boston Scientific Corporation | $18.14 | 2022 | |
| Braintree Laboratories, INC. | $15.53 | 2023 | Sutab |
| Redhill Biopharma INC. | $14.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Banner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.